Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Sunitinib

Sunitinib

Sunitinib is a multitargeted tyrosine kinasee inhibitor used in the treatment of various cancers, including advanced renal cell carcinoma and gastrointestinal stromal tumors.
It works by inhibiting multiple receptor tyrosine kinases involved in tumor growth, angiogenesis, and metastatic progression.
Sunitinib has demonstrated efficacy in improving progression-free survival and overall survival in patients with these malignancies.
Researchers can optimize Sunitinib studies using PubCompare.ai's AI-driven protocol comparisons to locate the best protocols from literature, preprints, and patents, achieving reproducible and accurate results for their Sunitinib research.

Most cited protocols related to «Sunitinib»

1
HUVEC network formation with VEGF-A
Cited 89 times
Network formation in the ETFA was carried out by seeding HUVEC (105 cells/well) on Matrigel (250 µl/well) into a 24-well plate for 24 h at 37 °C with 5% CO2. Cells were suspended in EGM2-MV medium without VEGF-A (control condition), or complemented with 5, 10, 25 or 50 ng/ml VEGF-A. Sunitinib, a multitargeted tyrosine kinase inhibitor was added (5 nM or 25 nM) to culture medium as an angiogenesis inhibitor. Five pictures per well (center of the well and four cardinal points) were taken at time 24 h using a camera Nikon D5300 associated to an inverted microscope Nikon Eclipse TS100 using a 4× objective (NA 0.13) in phase contrast mode without fixation. For statistical analyses, three wells were seeded per conditions.
Carpentier G., Berndt S., Ferratge S., Rasband W., Cuendet M., Uzan G, & Albanese P. (2020). Angiogenesis Analyzer for ImageJ — A comparative morphometric analysis of “Endothelial Tube Formation Assay” and “Fibrin Bead Assay”. Scientific Reports, 10, 11568.
Full text: Click here
Publication 2020
Angiogenesis Inhibitors Cells Complement 5 Culture Media matrigel Microscopy Microscopy, Phase-Contrast Sunitinib Vascular Endothelial Growth Factors
2
Metastatic RCC Anti-VEGF Targeted Treatments
Cited 30 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Axitinib Bevacizumab Ethics Committees, Research Immunotherapy Malignant Neoplasms MTOR Inhibitors Patients pazopanib Sorafenib Sunitinib Vascular Endothelial Growth Factors
3
Nivolumab plus Ipilimumab versus Sunitinib for RCC
Cited 21 times
This was a randomized, open-label, phase 3 trial of nivolumab plus ipilimumab followed by nivolumab monotherapy versus sunitinib monotherapy. Randomization (in a 1:1 ratio) was performed with a block size of 4 with stratification according to IMDC risk score (0 vs. 1 or 2 vs. 3 to 6) and geographic region (United States vs. Canada and Europe vs. the rest of the world).
Nivolumab and ipilimumab were administered intravenously at a dose of 3 mg per kilogram over a period of 60 minutes and 1 mg per kilogram over a period of 30 minutes, respectively, every 3 weeks for four doses (induction phase), followed by nivolumab monotherapy at a dose of 3 mg per kilogram every 2 weeks (maintenance phase). Sunitinib was administered at a dose of 50 mg orally once daily for 4 weeks of each 6-week cycle. No dose reductions were allowed for nivolumab or ipilimumab. Dose delays for adverse events were permitted in both groups. Patients treated with nivolumab plus ipilimumab had to discontinue both nivolumab and ipilimumab if they had a treatment-related adverse event during the induction phase that required discontinuation, and they could not continue on to nivolumab maintenance therapy. Detailed discontinuation criteria are shown in the Supplementary Appendix, available with the full text of this article at NEJM.org.
A November 2017 protocol amendment, after the primary end point had been met, permitted crossover from the sunitinib group to the nivolumab-plus-ipilimumab group. Nivolumab, ipilimumab, and sunitinib were provided by the sponsors, except when sunitinib was procured as a local commercial product in certain countries.
Motzer R.J., Tannir N.M., McDermott D.F., Frontera O.A., Melichar B., Choueiri T.K., Plimack E.R., Barthélémy P., Porta C., George S., Powles T., Donskov F., Neiman V., Kollmannsberger C.K., Salman P., Gurney H., Hawkins R., Ravaud A., Grimm M.O., Bracarda S., Barrios C.H., Tomita Y., Castellano D., Rini B.I., Chen A.C., Mekan S., McHenry M.B., Wind-Rotolo M., Doan J., Sharma P., Hammers H.J, & Escudier B. (2018). Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine, 378(14), 1277-1290.
Publication 2018
Drug Tapering Ipilimumab Nivolumab Patients Sunitinib Therapeutics
4
CheckMate 9ER: Nivolumab and Cabozantinib
Cited 17 times
CheckMate 9ER is a phase 3, randomized, openlabel trial of nivolumab combined with cabozantinib as compared with sunitinib monotherapy. Patients underwent randomization in a 1:1 ratio and were stratified according to IMDC prognostic risk score (0 [favorable] vs. 1 or 2 [intermediate] vs. 3 to 6 [poor]),18 (link),19 (link) geographic region (United States and Europe vs. the rest of the world), and tumor expression of the PD-1 ligand PD-L1 (≥1% vs. <1% or indeterminate). Specific risk factors that make up the IMDC score are included in the Supplementary Appendix, available at NEJM.org. Nivolumab was administered intravenously at a dose of 240 mg every 2 weeks, and cabozantinib was administered orally at a dose of 40 mg once daily. Sunitinib was administered orally at a dose of 50 mg once daily for 4 weeks, followed by 2 weeks off (6-week cycle). All trial treatment continued until disease progression or unacceptable toxic effects, with a maximum 2-year duration of nivolumab treatment. Crossover between groups was not permitted. Dose reductions were not allowed for nivolumab but were permitted for cabozantinib and sunitinib, according to the protocol. Dose delays for adverse events were permitted for all trial drugs. Discontinuation assessments for nivolumab and cabozantinib were made separately for each drug; if discontinuation criteria were met for only one drug, treatment could continue with the other drug that was not related to the observed toxic effect, according to the protocol. Dose-reduction specifications and discontinuation criteria for both groups are detailed in the trial protocol.
Choueiri T.K., Powles T., Burotto M., Escudier B., Bourlon M.T., Zurawski B., Oyervides Juárez V.M., Hsieh J.J., Basso U., Shah A.Y., Suárez C., Hamzaj A., Goh J.C., Barrios C., Richardet M., Porta C., Kowalyszyn R., Feregrino J.P., Żołnierek J., Pook D., Kessler E.R., Tomita Y., Mizuno R., Bedke J., Zhang J., Maurer M.A., Simsek B., Ejzykowicz F., Schwab G.M., Apolo A.B, & Motzer R.J. (2021). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine, 384(9), 829-841.
Publication 2021
cabozantinib CD274 protein, human Disease Progression Drug Tapering Ligands Neoplasms Nivolumab Patients Pharmaceutical Preparations Sunitinib
5
Immune Signature Predicts Response to Avelumab and Axitinib in Renal Cell Carcinoma
Cited 16 times
Blinded to clinical outcome, co-expression network analysis using WGCNA identified an immune response module of 306 genes and high expression of this 306-gene signature was associated with better PFS in the avelumab + axitinib arm but not in the sunitinib arm. To refine the 306-gene immune response module, we selected genes annotated for immune-related functionality and had univariate Cox PH p-value <0.01 in the combination arm. Together with the manually added CD8B gene, which barely misses the p-value=0.01 cutoff, we defined a 26-gene JAVELIN Renal 101 Immuno signature. Further consensus WGCNA analysis identified a consensus 414-gene immune response module that was associated with better PFS in the avelumab + axitinib arm but not in the sunitinib arm. All 26 genes in the JAVELIN Renal 101 Immuno signature are also in the consensus 414-gene module, verifying the robustness of the signature. Validation of the 26-gene signature was carried out using two independent datasets: the first derived from patients with advanced RCC enrolled in the single-arm, phase 1b JAVELIN Renal 100 clinical trial who received avelumab + axitinib (NCT02493751)6 (link) and the second derived from a mixed solid tumor cohort from the avelumab monotherapy phase 1 JAVELIN Solid Tumor study (NCT01772004)1 (link),7 . A similar approach was used to define the JAVELIN Renal 101 Angio signature, in which top genes associated with better PFS in the sunitinib arm were identified.
Motzer R.J., Robbins P.B., Powles T., Albiges L., Haanen J.B., Larkin J., Mu X.J., Ching K.A., Uemura M., Pal S.K., Alekseev B., Gravis G., Campbell M.T., Penkov K., Lee J.L., Hariharan S., Wang X., Zhang W., Wang J., Chudnovsky A., di Pietro A., Donahue A.C, & Choueiri T.K. (2020). Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature medicine, 26(11), 1733-1741.
Publication 2020
avelumab Axitinib Gene Modules Genes Immune System Processes Kidney Mixed Salivary Gland Tumor Neoplasms Patients Response, Immune Sunitinib

Most recents protocols related to «Sunitinib»

1
Metastatic Renal Cell Carcinoma Protocol
Patients who met the following inclusion criteria were enrolled in the study: (1) aged ≥ 20 years with a documented histological or cytological diagnosis of ccRCC; (2) measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and determined by investigators; (3) had received at least one prior VEGFR-TKI therapy (e.g., sorafenib, sunitinib, axitinib, pazopanib, and tivozanib). Further detailed inclusion and exclusion criteria are described in our previous report [16 (link)].
Nakaigawa N., Tomita Y., Tamada S., Tatsugami K., Osawa T., Oya M., Kanayama H., Miura Y., Sassa N., Nishimura K., Nozawa M., Masumori N., Miyoshi Y., Kuroda S, & Kimura A. (2023). Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. International Journal of Clinical Oncology, 28(3), 416-426.
Full text: Click here
Publication 2023
Axitinib Diagnosis FLT1 protein, human Patients pazopanib Sorafenib Sunitinib Therapeutics tivozanib
2
RNA-seq Analysis of A375 Cell Response
A375 cells were treated with DMSO, 4 μM sunitinib, 1 μM JQ-1, or 4 μM sunitinib + 1 μM JQ-1 for 24 h. Total RNA was extracted with MagZol and used for RNA-seq analysis. Libraries were constructed and sequenced on a BGISEQ-500RS sequencer. Only genes with at least 1 read in each of the six samples and at least 50 reads in total among all samples were retained for subsequent analyses. Differentially expressed genes were defined as those with a | log2-fold-change | > 1 and q value < 0.05.
Zeng F., Li Y., Meng Y., Sun H., He Y., Yin M., Chen X, & Deng G. (2023). BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Experimental & Molecular Medicine, 55(2), 364-376.
Full text: Click here
Publication 2023
Cells Genes RNA-Seq Sulfoxide, Dimethyl Sunitinib
3
Evaluating NHWD-870 and Sunitinib for A375 Xenograft
All animal experiments were performed in accordance with protocols approved by the Ethical Review of Experimental Animals committee at Central South University. A375 cells (2 × 106) were suspended in 100 μl of PBS and inoculated into nude mice (Shanghai SLAC). Tumor-bearing mice were randomly allocated into groups. When the tumor volume reached 50-100 mm3, the mice were treated with vehicle (corn oil + citrate buffer (0.1 mol/L, pH = 3.5), orally), NHWD-870 (in corn oil, 0.75 mg/kg, orally), sunitinib (in citrate buffer, 40 mg/kg, orally), or a combination of both drugs for two days, and treatment was then stopped for one day. This process was repeated for the duration of the treatment period. The tumor size was recorded every three days, and the volume was calculated as [(length × width × width) / 2].
Zeng F., Li Y., Meng Y., Sun H., He Y., Yin M., Chen X, & Deng G. (2023). BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Experimental & Molecular Medicine, 55(2), 364-376.
Full text: Click here
Publication 2023
Animals, Laboratory Buffers Cells Citrates Corn oil Drug Combinations Mice, Nude Mus Neoplasms Sunitinib
4
Metastatic Renal Cell Carcinoma Treatment Outcomes

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Administration, Oral avelumab Axitinib cabozantinib Index, Body Mass Intravenous Infusion Ipilimumab Neoplasms Nivolumab Patients pazopanib pembrolizumab Pharmaceutical Preparations Prognostic Factors Sunitinib Treatment Protocols
5
Combining AIs and ICIs for Cancer
The AIs included anlotinib, apatinib, and sunitinib. The ICIs included sintilimab, toripalimab, camrelizumab, and pembrolizumab. The treatment regimens are listed in Supplementary Table S1. Follow-up was routinely conducted every three months.
Liu Z., Xu J., Liu M., Hu W., Xu N, & Zhu D. (2023). Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study. Scientific Reports, 13, 3385.
Full text: Click here
Publication 2023
anlotinib apatinib camrelizumab pembrolizumab sintilimab Sunitinib toripalimab Treatment Protocols

Top products related to «Sunitinib»

1
Sunitinib by Selleck Chemicals
Sourced in United States, Germany, China
Sunitinib is a small-molecule inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptors (PDGFR) α and β, stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), and the receptor encoded by the RET proto-oncogene.
2
Sunitinib by Merck Group
Sourced in United States, Germany, France
Sunitinib is a multi-kinase inhibitor used as a laboratory tool. It functions by inhibiting various receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and stem cell factor receptor (KIT).
3
Sunitinib by LC Laboratories
Sourced in United States
Sunitinib is a small-molecule tyrosine kinase inhibitor product used for research purposes. It inhibits multiple receptor tyrosine kinases involved in tumor growth, angiogenesis, and metastatic progression.
4
Sunitinib by Pfizer
Sourced in United States
Sunitinib is a laboratory equipment product used for research and development purposes. It functions as a multi-targeted receptor tyrosine kinase inhibitor.
5
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
6
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
7
Rpmi 1640 medium by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
8
Imatinib by Selleck Chemicals
Sourced in United States, Germany, United Kingdom, China, France
Imatinib is a tyrosine kinase inhibitor. It is a laboratory reagent used in research applications.
9
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
10
Sorafenib by Selleck Chemicals
Sourced in United States, China, Germany, Australia
Sorafenib is a laboratory reagent that functions as a multi-kinase inhibitor. It is commonly used in research settings to study cellular signaling pathways and their modulation.

More about "Sunitinib"

Sunitinib is a multitargeted receptor tyrosine kinase (RTK) inhibitor that has demonstrated remarkable efficacy in the treatment of various cancers, including advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST).
This small-molecule drug works by inhibiting multiple RTKs involved in tumor growth, angiogenesis, and metastatic progression, making it a potent anticancer agent.
Researchers can leverage the power of AI-driven protocol comparisons using tools like PubCompare.ai to optimize their Sunitinib studies.
By identifying the best protocols from literature, preprints, and patents, researchers can achieve reproducible and accurate results, streamlining their Sunitinib-related research.
This approach can be particularly useful when exploring the combination of Sunitinib with other compounds, such as the tyrosine kinase inhibitor Imatinib or the multikinase inhibitor Sorafenib, which have also shown promise in cancer treatment.
In addition to Sunitinib, researchers may also utilize cell culture systems involving DMSO (dimethyl sulfoxide) as a solvent, FBS (fetal bovine serum) as a growth supplement, and RPMI 1640 medium as a nutrient-rich environment for cell lines.
The inclusion of Penicillin/streptomycin can help prevent bacterial contamination in these in vitro experiments.
By optimizing Sunitinib studies and exploring synergistic combinations with other therapeutic agents, researchers can unlock new insights and advance the understanding of this multitargeted tyrosine kinase inhibitor's potential in the fight against cancer.
The AI-powered protocol comparisons provided by PubCompare.ai can be a valuable tool in this endeavor, enabling researchers to make informed decisions and achieve more reliable and impactful results.